Available Trials

Colorectal Cancer

A Phase II Study of the Dual Immune Checkpoint Blockade With Durvalumab (MEDI4736) Plus Tremelimumab Following Palliative Hypofractionated Radiation in Patients With Microsatellite Stable (MSS) Metastatic Colorectal Cancer Progressing on Chemotherapy
  • Disease/Condition: Colon | Rectum
  • Principal Investigator: Jeremy Kortmansky
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
  • Disease/Condition: Anus | Bladder | Breast - Female | Breast - Male | Cervix Uteri | Colon | Corpus Uteri | Esophagus | Eye and Orbit | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Pediatrics
  • Principal Investigator: Nina Kadan-Lottick
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • Disease/Condition: Anus | Bladder | Colon | Esophagus | Kidney | Lip, Oral Cavity and Pharynx | Lung | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Stomach | Thyroid | Unknown Sites | Breast
  • Principal Investigator: Hari Anant Deshpande
An Open-Label, Phase 1, First-In-Human Study of Safety and Tolerability of TRAIL Receptor Agonist ABBV-621 in Subjects With Previously Treated Solid Tumors and Hematologic Malignancies
  • Disease/Condition: Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Myeloid and Monocytic Leukemia | Non-Hodgkin's Lymphoma | Pancreas | Prostate | Rectum | Small Intestine | Stomach | Thyroid | Phase I | Anus | Bladder | Breast - Female | Breast - Male | Colon | Esophagus | Kidney | Larynx
  • Principal Investigator: Patricia LoRusso
Medication Adherence in Patients Treated with Capecitabine
  • Disease/Condition: Colon | Breast
  • Principal Investigator: Sarah Mougalian
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors
  • Disease/Condition: Anus | Bladder | Bones and Joints | Brain and Nervous System | Breast - Female | Breast - Male | Cervix Uteri | Colon | Corpus Uteri | Esophagus | Eye and Orbit | Kaposi's sarcoma | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Mycosis Fungoides | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Phase I
  • Principal Investigator: Patricia LoRusso
A Phase I/II Study of Safety and Efficacy of Ribociclib (LEE011) in Combination With Trametinib (TMT212) in Patients With Metastatic or Advanced Solid Tumors
  • Disease/Condition: Anus | Bladder | Bones and Joints | Brain and Nervous System | Breast - Female | Breast - Male | Cervix Uteri | Colon | Esophagus | Eye and Orbit | Kaposi's sarcoma | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Phase I
  • Principal Investigator: Patricia LoRusso
Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone or in Combination With Nivolumab in Adult Subjects With Advanced Refractory Solid Tumor Malignancies
  • Disease/Condition: Anus | Bladder | Bones and Joints | Brain and Nervous System | Breast - Female | Breast - Male | Cervix Uteri | Colon | Corpus Uteri | Esophagus | Eye and Orbit | Kaposi's sarcoma | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Digestive Organ | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Phase I
  • Principal Investigator: Patricia LoRusso
TAS-102 and Oxaliplatin (TAS-OX) for Refractory Metastatic Colon Cancer
  • Disease/Condition: Colon
  • Principal Investigator: Jeremy Kortmansky
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
  • Disease/Condition: Anus | Bladder | Bones and Joints | Brain and Nervous System | Breast - Female | Breast - Male | Cervix Uteri | Colon | Corpus Uteri | Esophagus | Eye and Orbit | Hodgkin's Lymphoma | Kaposi's sarcoma | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Lymphoid Leukemia | Melanoma, skin | Non-Hodgkin's Lymphoma | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid
  • Principal Investigator: Scott Nicholas Gettinger

Gastric and Esophageal

A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
  • Disease/Condition: Anus | Bladder | Breast - Female | Breast - Male | Cervix Uteri | Colon | Corpus Uteri | Esophagus | Eye and Orbit | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Pediatrics
  • Principal Investigator: Nina Kadan-Lottick
A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Hyaluronan-High (HA-high) Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
  • Disease/Condition: Other Digestive Organ
  • Principal Investigator: Stacey M Stein
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • Disease/Condition: Anus | Bladder | Colon | Esophagus | Kidney | Lip, Oral Cavity and Pharynx | Lung | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Stomach | Thyroid | Unknown Sites | Breast
  • Principal Investigator: Hari Anant Deshpande
A Phase 1/2 Study of Olaparib in Combination With Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)
  • Disease/Condition: Other Digestive Organ | Stomach
  • Principal Investigator: Jill Lacy
Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY94-9343) in Patients With Mesothelin Expressing Advanced or Recurrent Malignancies
  • Disease/Condition: Other Digestive Organ | Pancreas | Stomach
  • Principal Investigator: Stacey M Stein
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants With Advanced Gastric Cancer (FRACTION-Gastric Cancer)
  • Disease/Condition: Esophagus | Other Digestive Organ | Stomach
  • Principal Investigator: Stacey M Stein
An Open-Label, Phase 1, First-In-Human Study of Safety and Tolerability of TRAIL Receptor Agonist ABBV-621 in Subjects With Previously Treated Solid Tumors and Hematologic Malignancies
  • Disease/Condition: Anus | Bladder | Breast - Female | Breast - Male | Colon | Esophagus | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Myeloid and Monocytic Leukemia | Non-Hodgkin's Lymphoma | Pancreas | Prostate | Rectum | Small Intestine | Stomach | Thyroid | Phase I
  • Principal Investigator: Patricia LoRusso
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors
  • Disease/Condition: Anus | Bladder | Bones and Joints | Brain and Nervous System | Breast - Female | Breast - Male | Cervix Uteri | Colon | Corpus Uteri | Esophagus | Eye and Orbit | Kaposi's sarcoma | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Mycosis Fungoides | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Phase I
  • Principal Investigator: Patricia LoRusso
A Phase I/II Study of Safety and Efficacy of Ribociclib (LEE011) in Combination With Trametinib (TMT212) in Patients With Metastatic or Advanced Solid Tumors
  • Disease/Condition: Anus | Bladder | Bones and Joints | Brain and Nervous System | Breast - Female | Breast - Male | Cervix Uteri | Colon | Esophagus | Eye and Orbit | Kaposi's sarcoma | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Phase I
  • Principal Investigator: Patricia LoRusso
Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone or in Combination With Nivolumab in Adult Subjects With Advanced Refractory Solid Tumor Malignancies
  • Disease/Condition: Anus | Bladder | Bones and Joints | Brain and Nervous System | Breast - Female | Breast - Male | Cervix Uteri | Colon | Corpus Uteri | Esophagus | Eye and Orbit | Kaposi's sarcoma | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Digestive Organ | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Phase I
  • Principal Investigator: Patricia LoRusso

Liver Cancer

A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
  • Disease/Condition: Anus | Bladder | Breast - Female | Breast - Male | Cervix Uteri | Colon | Corpus Uteri | Esophagus | Eye and Orbit | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Pediatrics
  • Principal Investigator: Nina Kadan-Lottick
An Open-Label, Phase 1, First-In-Human Study of Safety and Tolerability of TRAIL Receptor Agonist ABBV-621 in Subjects With Previously Treated Solid Tumors and Hematologic Malignancies
  • Disease/Condition: Anus | Bladder | Breast - Female | Breast - Male | Colon | Esophagus | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Myeloid and Monocytic Leukemia | Non-Hodgkin's Lymphoma | Pancreas | Prostate | Rectum | Small Intestine | Stomach | Thyroid | Phase I
  • Principal Investigator: Patricia LoRusso
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors
  • Disease/Condition: Anus | Bladder | Bones and Joints | Brain and Nervous System | Breast - Female | Breast - Male | Cervix Uteri | Colon | Corpus Uteri | Esophagus | Eye and Orbit | Kaposi's sarcoma | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Mycosis Fungoides | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Phase I
  • Principal Investigator: Patricia LoRusso
A Phase I/II Study of Safety and Efficacy of Ribociclib (LEE011) in Combination With Trametinib (TMT212) in Patients With Metastatic or Advanced Solid Tumors
  • Disease/Condition: Anus | Bladder | Bones and Joints | Brain and Nervous System | Breast - Female | Breast - Male | Cervix Uteri | Colon | Esophagus | Eye and Orbit | Kaposi's sarcoma | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Phase I
  • Principal Investigator: Patricia LoRusso
Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone or in Combination With Nivolumab in Adult Subjects With Advanced Refractory Solid Tumor Malignancies
  • Disease/Condition: Anus | Bladder | Bones and Joints | Brain and Nervous System | Breast - Female | Breast - Male | Cervix Uteri | Colon | Corpus Uteri | Esophagus | Eye and Orbit | Kaposi's sarcoma | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Digestive Organ | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Phase I
  • Principal Investigator: Patricia LoRusso
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy
  • Disease/Condition: Liver | Other Digestive Organ
  • Principal Investigator: Stacey M Stein
A Phase II Trial of Systemic Chemotherapy (Gemcitabine and Cisplatin) in Combination with Conventional Transarterial Chemoembolization (cTACE) in Patients with Advanced Intra-Hepatic Cholangiocarcinoma (ICC)
  • Disease/Condition: Liver
  • Principal Investigator: Todd Schlachter
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
  • Disease/Condition: Anus | Bladder | Bones and Joints | Brain and Nervous System | Breast - Female | Breast - Male | Cervix Uteri | Colon | Corpus Uteri | Esophagus | Eye and Orbit | Hodgkin's Lymphoma | Kaposi's sarcoma | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Lymphoid Leukemia | Melanoma, skin | Non-Hodgkin's Lymphoma | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid
  • Principal Investigator: Scott Nicholas Gettinger
A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab With or Without Ipilimumab in Advanced Solid Tumors
  • Disease/Condition: Anus | Bladder | Bones and Joints | Brain and Nervous System | Breast - Female | Breast - Male | Cervix Uteri | Colon | Esophagus | Eye and Orbit | Kaposi's sarcoma | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Phase I
  • Principal Investigator: Patricia LoRusso
A Study of Intravenous RO6895882 and MPDL3280A Combination in Patients With Locally Advanced and/or Metastatic Solid Tumors
  • Disease/Condition: Anus | Bladder | Breast - Female | Colon | Esophagus | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Phase I | Unknown Sites
  • Principal Investigator: Joseph Paul Eder

Pancreatic Cancer

A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
  • Disease/Condition: Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Pediatrics | Anus | Bladder | Breast - Female | Breast - Male | Cervix Uteri | Colon | Corpus Uteri | Esophagus | Eye and Orbit | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital
  • Principal Investigator: Nina Kadan-Lottick
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • Disease/Condition: Anus | Bladder | Colon | Esophagus | Kidney | Lip, Oral Cavity and Pharynx | Lung | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Stomach | Thyroid | Unknown Sites | Breast
  • Principal Investigator: Hari Anant Deshpande
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
  • Disease/Condition: Pancreas
  • Principal Investigator: Jill Lacy
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
  • Disease/Condition: Pancreas
  • Principal Investigator: Jill Lacy
Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY94-9343) in Patients With Mesothelin Expressing Advanced or Recurrent Malignancies
  • Disease/Condition: Other Digestive Organ | Pancreas | Stomach
  • Principal Investigator: Stacey M Stein
Phase II Study to Evaluate Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma
  • Disease/Condition: Pancreas
  • Principal Investigator: Kimberly L. Johung
An Open-Label, Phase 1, First-In-Human Study of Safety and Tolerability of TRAIL Receptor Agonist ABBV-621 in Subjects With Previously Treated Solid Tumors and Hematologic Malignancies
  • Disease/Condition: Anus | Bladder | Breast - Female | Breast - Male | Colon | Esophagus | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Myeloid and Monocytic Leukemia | Non-Hodgkin's Lymphoma | Pancreas | Prostate | Rectum | Small Intestine | Stomach | Thyroid | Phase I
  • Principal Investigator: Patricia LoRusso
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors
  • Disease/Condition: Anus | Bladder | Bones and Joints | Brain and Nervous System | Breast - Female | Breast - Male | Cervix Uteri | Colon | Corpus Uteri | Esophagus | Eye and Orbit | Kaposi's sarcoma | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Mycosis Fungoides | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Phase I
  • Principal Investigator: Patricia LoRusso
A Phase I/II Study of Safety and Efficacy of Ribociclib (LEE011) in Combination With Trametinib (TMT212) in Patients With Metastatic or Advanced Solid Tumors
  • Disease/Condition: Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Phase I | Anus | Bladder | Bones and Joints | Brain and Nervous System | Breast - Female | Breast - Male | Cervix Uteri | Colon | Esophagus | Eye and Orbit | Kaposi's sarcoma | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Urinary | Ovary | Pancreas | Prostate
  • Principal Investigator: Patricia LoRusso
An Open-label, Phase II Study of Intravenous Anetumab Ravtansine (BAY 94-9343), an Anti-mesothelin Antibody Drug Conjugate, in Pretreated Mesothelin-expressing Advanced Pancreatic Cancer
  • Disease/Condition: Pancreas
  • Principal Investigator: Stacey M Stein